STOCK TITAN
  1. Home
  2. Sec-filings
  3. GPCR
  4. [Form 4] Structure Therapeutics Inc. Insider Trading Activity

Structure Therapeutics (GPCR) CSO sells 3,939 ADS after option exercise

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Structure Therapeutics chief scientific officer Xichen Lin exercised options for 11,817 Ordinary Shares at $0.34 per share on August 4, 2026, converted them into 3,939 American Depositary Shares, and sold all ADS in two trades at weighted average prices of $49.2857 and $50.0290 pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026. Following this partial exercise, a share option over 154,715 Ordinary Shares remains outstanding.

Positive

  • None.

Negative

  • None.
Insider Lin Xichen
Role CHIEF SCIENTIFIC OFFICER
Sold 3,939 shs ($195K)
Type Security Shares Price Value
Exercise Share Option (right to buy) F1, F3, F4 11,817 $0.00 $0.00
Conversion American Depositary Shares F5, F6 3,939 $0.00 $0.00
Sale American Depositary Shares F5, F7, F8, F9 3,100 $49.2857 $153K
Sale American Depositary Shares F5, F7, F8, F10 839 $50.029 $42K
Exercise Ordinary Shares F1 11,817 $0.34 $4K
Conversion Ordinary Shares F2 11,817 $0.00 $0.00
Holdings After Transaction: Share Option (right to buy) — 154,715 shares (Direct); American Depositary Shares — 0 shares (Direct); Ordinary Shares — 228,960 shares (Direct)
Footnotes (10)
  1. F1. Reflects price per share in Ordinary Shares.
  2. F2. The Ordinary Shares were converted into American Depositary Shares as reported in Table II.
  3. F3. 1/4 of the Ordinary Shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the Ordinary Shares vested in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
  4. F4. This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 11,817 Ordinary Shares.
  5. F5. Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date.
  6. F6. 11,817 Ordinary Shares, which were acquired upon exercise of a share option, were converted into 3,939 American Depositary Shares.
  7. F7. The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026.
  8. F8. Reflects price per share in American Depositary Shares.
  9. F9. The weighted average sale price for the transaction reported was $49.2857 and the range of prices were between $48.66 and $49.65. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.
  10. F10. The weighted average sale price for the transaction reported was $50.0290, and the range of prices were between $49.69 and $50.33. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.
Options exercised 11,817 Ordinary Shares Shares acquired on 2026-08-04 upon option exercise at $0.34 per share
Exercise price $0.34 per Ordinary Share Conversion or exercise price for the share option exercised on 2026-08-04
ADS converted 3,939 American Depositary Shares ADS received by converting 11,817 Ordinary Shares on 2026-08-04
ADS sold (block 1) 3,100 American Depositary Shares Sold at weighted average price $49.2857 per ADS on 2026-08-04
ADS sold (block 2) 839 American Depositary Shares Sold at weighted average price $50.0290 per ADS on 2026-08-04
Options remaining 154,715 Ordinary Shares Ordinary Shares remaining under the share option after partial exercise
ADS conversion ratio 3 Ordinary Shares per ADS Each American Depositary Share is convertible into three Ordinary Shares
American Depositary Shares financial
"Each American Depositary Share is convertible at any time into three Ordinary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
Rule 10b5-1 trading plan financial
"The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
share option financial
"This reflects the number of Ordinary Shares remaining under the share option"
Vesting Commencement Date financial
"1/4 of the Ordinary Shares vested one year after July 22, 2019, the Vesting Commencement Date"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
weighted average sale price financial
"The weighted average sale price for the transaction reported was $49.2857"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transactions did Structure Therapeutics (GPCR) report for Xichen Lin?
Structure Therapeutics reported that CSO Xichen Lin exercised 11,817 options at $0.34 per Ordinary Share, converted them into 3,939 ADS, and sold all ADS in two trades on August 4, 2026 under a Rule 10b5-1 plan.

How many Structure Therapeutics (GPCR) ADS did Xichen Lin sell and at what prices?
Xichen Lin sold 3,100 ADS at a weighted average price of $49.2857 and 839 ADS at a weighted average price of $50.0290. All 3,939 ADS sold came from the same option exercise and share conversion.

Were the GPCR insider sales by Xichen Lin under a Rule 10b5-1 trading plan?
Yes. The filing and related footnotes state that the American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026, and the form’s Rule 10b5-1 checkbox is marked true.

What options remain for Structure Therapeutics (GPCR) CSO Xichen Lin after these trades?
After partially exercising a share option for 11,817 Ordinary Shares, Xichen Lin still holds an option over 154,715 Ordinary Shares. A footnote explains this is the number of Ordinary Shares remaining under the option following the partial exercise.

What is the conversion ratio between ADS and Ordinary Shares for Structure Therapeutics (GPCR)?
Each American Depositary Share of Structure Therapeutics is convertible into three Ordinary Shares. Footnotes clarify that 11,817 Ordinary Shares acquired on exercise were converted into 3,939 ADS, and that ADS have no expiration date.

What vesting terms applied to the Structure Therapeutics (GPCR) options exercised by Xichen Lin?
The exercised share option vested 25% one year after the July 22, 2019 vesting commencement date, with the remaining 75% vesting in 36 equal monthly installments starting from that first anniversary, according to the footnote description.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lin Xichen
(Last)(First)(Middle)
C/O STRUCTURE THERAPEUTICS INC.
601 GATEWAY BLVD., SUITE 900
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF SCIENTIFIC OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares08/04/2026M11,817A$0.34(1)240,777D
Ordinary Shares08/04/2026C11,817(2)D$0228,960D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option (right to buy)$0.34(1)08/04/2026M11,817 (3)09/10/2029Ordinary Shares11,817$0154,715(4)D
American Depositary Shares(5)08/04/2026C3,939(6) (5) (5)Ordinary Shares11,817$03,939D
American Depositary Shares(5)08/04/2026S(7)3,100 (5) (5)Ordinary Shares9,300$49.2857(8)(9)839D
American Depositary Shares(5)08/04/2026S(7)839 (5) (5)Ordinary Shares2,517$50.029(8)(10)0D
Explanation of Responses:
1. Reflects price per share in Ordinary Shares.
2. The Ordinary Shares were converted into American Depositary Shares as reported in Table II.
3. 1/4 of the Ordinary Shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the Ordinary Shares vested in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
4. This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 11,817 Ordinary Shares.
5. Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date.
6. 11,817 Ordinary Shares, which were acquired upon exercise of a share option, were converted into 3,939 American Depositary Shares.
7. The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026.
8. Reflects price per share in American Depositary Shares.
9. The weighted average sale price for the transaction reported was $49.2857 and the range of prices were between $48.66 and $49.65. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.
10. The weighted average sale price for the transaction reported was $50.0290, and the range of prices were between $49.69 and $50.33. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.
/s/ Jun Yoon, Attorney-in-Fact08/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR